Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lanthanum carbonate
Drug ID BADD_D01247
Description Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led to severe choking. It is prescribed for treating high phosphate levels, mainly found in patients with chronic kidney disease. Lanthanum should be taken with meals and binds to phosphate in the diet, preventing phosphate absorption in the intestine.
Indications and Usage Used to reduce serum phosphate in patients with end stage renal disease (ESRD).
Marketing Status approved
ATC Code V03AE03
DrugBank ID DB06792
KEGG ID D04667
MeSH ID C119467
PubChem ID 168924
TTD Drug ID D0H1LO
NDC Product Code 0093-5939; 0093-5940; 71052-658; 66993-422; 68180-820; 65015-728; 66022-0116; 0093-5938; 54092-252; 54092-256; 66993-423; 69097-934; 76282-477; 68180-821; 54092-253; 68180-819; 66993-424; 76282-478; 69097-936; 76282-476; 49964-0035; 54092-254; 69097-935; 54092-257
UNII 490D9F069T
Synonyms lanthanum carbonate | lantharenol | Fosrenol
Chemical Information
Molecular Formula La2(CO3)3
CAS Registry Number 587-26-8
SMILES C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[La+3].[La+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.004585%Not Available
Abdominal distension07.01.04.0010.003098%
Abdominal pain07.01.05.0020.001859%
Abdominal pain upper07.01.05.0030.004833%
Anaemia01.03.02.0010.003098%
Arrhythmia02.03.02.0010.001239%Not Available
Aspiration22.02.07.0070.002478%
Atrial fibrillation02.03.03.0020.001239%
Bezoar07.11.01.0080.015365%Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Cardiac failure02.05.01.0010.001859%
Cardiomyopathy02.04.01.0010.001239%Not Available
Cholecystitis09.03.01.0010.001239%
Condition aggravated08.01.03.0040.005452%Not Available
Confusional state19.13.01.001; 17.02.03.0050.003098%
Constipation07.02.02.0010.012515%
Cough22.02.03.0010.001239%
Death08.04.01.0010.027880%
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Diabetes mellitus05.06.01.001; 14.06.01.0010.001239%Not Available
Diarrhoea07.02.01.001--
Drug ineffective08.06.01.0060.032837%Not Available
Drug interaction08.06.03.0010.002726%Not Available
Dysgeusia17.02.07.003; 07.14.03.0010.004213%
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.005824%
Feeling abnormal08.01.09.0140.001239%Not Available
Gastric cancer07.21.02.001; 16.13.03.0010.001239%Not Available
Gastric ulcer07.04.03.0020.002478%
Gastritis erosive07.04.03.0030.004337%Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages